New cocktail of 6 drugs takes on tough lymphomas
NCT ID NCT04739813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions over up to six 21-day cycles, with long-term follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?